Next, we used selective BTK and PI3Kδ inhibitors (ibrutinib and GS-1101, respectively) to explore the functional role of BCR signalling in MCL survival and stroma-mediated drug resistance. The gene discussed is BCR; the disease is mantle cell lymphoma.